Precigen (PGEN) director reports sale of 235,467 shares of common stock on 12/12/2025

Rhea-AI Filing Summary

A director of Precigen, Inc. reported selling 235,467 shares of common stock on 12/12/2025. The shares were sold at a weighted average price of $3.6349, with individual trades executed at prices ranging from $3.5000 to $3.7100.

Following these sales, the director beneficially owns 110,603 shares of Precigen common stock in direct ownership. The filing notes that full details of the number of shares sold at each price within the stated range are available upon request.

Insider Trade Summary

Net Seller: 235,467 shares ($855,899)

Net Sell 1 txn

Insider KINDLER JEFFREY B

Role Director

Sold 235,467 shs ($856K)

Type	Security	Shares	Price	Value
Sale	Common Stock	235,467	$3.6349	$856K

Holdings After Transaction: Common Stock — 110,603 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KINDLER JEFFREY B

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		S		235,467	D	$3.6349(1)	110,603	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.5000 to $3.7100, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

	/s/ Jeffrey B. Kindler, by Donald P. Lehr, as attorney-in-fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider share transaction did Precigen (PGEN) report in this Form 4?

A Precigen director reported the sale of 235,467 shares of the companys common stock on 12/12/2025, as disclosed in Table I of the filing.

How many Precigen (PGEN) shares were sold and at what price?

The director sold 235,467 common shares at a weighted average price of $3.6349 per share, with individual trades occurring between $3.5000 and $3.7100.

How many Precigen (PGEN) shares does the director own after the sale?

After the reported transactions, the director beneficially owns 110,603 shares of Precigen common stock in direct ownership.

On what date did the Precigen (PGEN) directors stock sale occur?

The earliest transaction date reported for the Precigen directors sale of common stock is 12/12/2025.

Were multiple trade prices involved in the Precigen (PGEN) directors sale?

Yes. The filing states the reported price is a weighted average, with shares sold in multiple transactions at prices between $3.5000 and $3.7100, and the director undertakes to provide full price-by-price details upon request.

Does this Precigen (PGEN) Form 4 report any derivative securities transactions?

The excerpted Table II for derivative securities shows no listed acquisitions or dispositions of derivative securities for this reporting person.